Stereotactic Body Radiation Therapy with Integrated Boost for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer+5 More
Stereotactic Body Radiation Therapy with Integrated Boost - Radiation
Eligibility
18+
Male
What conditions do you have?
Select

Study Summary

This trial will study if it is safe and effective to give a higher radiation dose to the part of the prostate that contains cancer, while giving a standard dose to the whole prostate. The goal is to control the cancer while minimizing side effects.

Eligible Conditions
  • Prostate Cancer
  • Adenocarcinoma
  • Radiation Toxicity
  • Sexual Dysfunctions

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: Within 3 months of the completion of radiation therapy

Year 2
Treatment delivery quality assurance
Month 3
Early toxicity of SBRT with Integrated Boost for localized prostate cancer
Month 6
Early Efficacy
Late Quality of Life
Late Toxicity
Treatment planning feasibility

Trial Safety

Trial Design

1 Treatment Group

Stereotactic Body Radiation Therapy with Integrated Boost
1 of 1
Experimental Treatment

25 Total Participants · 1 Treatment Group

Primary Treatment: Stereotactic Body Radiation Therapy with Integrated Boost · No Placebo Group · N/A

Stereotactic Body Radiation Therapy with Integrated Boost
Radiation
Experimental Group · 1 Intervention: Stereotactic Body Radiation Therapy with Integrated Boost · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 3 months of the completion of radiation therapy

Who is running the clinical trial?

John Fiveash, MDLead Sponsor
John B Fiveash, MDPrincipal InvestigatorUniversity of Alabama at Birmingham Radiation Oncology
1 Previous Clinical Trials
60 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a combined Gleason score of <7.
You must have a histologically confirmed prostate adenocarcinoma.
You have a very low, low, or intermediate risk of developing a serious complication.
You have a life expectancy of at least 5 years.
You have a risk of malignant lymph node involvement of less than 15% as calculated on Partin tables.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: October 27th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.